ANS is committed to advancing, fostering, and promoting the development and application of nuclear sciences and technologies to benefit society.
Explore the many uses for nuclear science and its impact on energy, the environment, healthcare, food, and more.
Explore membership for yourself or for your organization.
Conference Spotlight
2026 ANS Annual Conference
May 31–June 3, 2026
Denver, CO|Sheraton Denver
Latest Magazine Issues
Apr 2026
Jan 2026
Latest Journal Issues
Nuclear Science and Engineering
April 2026
Nuclear Technology
February 2026
Fusion Science and Technology
May 2026
Latest News
Panelists discuss U.S. path to criticality in ANS webinar
The American Nuclear Society recently hosted a panel discussion featuring prominent figures from the nuclear sector who discussed the industry’s ongoing push for criticality.
Yasir Arafat, chief technical officer of Aalo Atomics; Jordan Bramble, CEO of Antares Nuclear; and Rita Baranwal, chief nuclear officer of Radiant Industries, participated in the discussion and covered their recent progress in the Department of Energy’s Reactor Pilot Program. Nader Satvat, director of nuclear systems design at Kairos Power, gave an update on the company’s ongoing demonstration projects taking place outside of the landscape of DOE authorization.
Martha Hultqvist, Irena Gudowska
Nuclear Technology | Volume 168 | Number 1 | October 2009 | Pages 123-127
Dose/Dose Rate | Special Issue on the 11th International Conference on Radiation Shielding and the 15th Topical Meeting of the Radiation Protection and Shielding Division (Part 1) / Radiation Protection | doi.org/10.13182/NT09-A9111
Articles are hosted by Taylor and Francis Online.
The mathematical anthropomorphic phantoms EVA-HIT and ADAM-HIT have been used in the Monte Carlo code SHIELD-HIT07 for simulations of lung tumor and prostate irradiation with light ions. Calculations were performed for 1H, 7Li, and 12C beams of energies in the range of 80 to 330 MeV/u. The secondary doses to organs, due to scattered primary ions and secondary particles produced in the phantoms, were studied taking into account the contribution from secondary neutrons, secondary protons, pions, and heavier fragments from helium to calcium. The doses to organs per dose to target (tumor) are of the order of 10-6 to 10-1 mGy Gy-1 and decrease with increasing distance from the target. In general the organ dose per target dose increases with increasing Z of the primary particle; however, for lighter primary ions (Z 3) and for organs close to the target, scattered primary particles show a nonnegligible dose contribution.